Loading
A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 2 interventional study registered as NCT05882058 by Boehringer Ingelheim, with 204 participants planned, started 2023-10-13 and due to reach its primary completion in 2027-12-17. Interventions recorded: BI 764532, dose 1, BI 764532, dose 2 and Ventana DLL3 RxDx assay.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Obrixtamig, Boehringer Ingelheim, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Obrixtamig, Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Boehringer Ingelheim and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/